Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease

NCT ID: NCT02946905

Last Updated: 2023-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

226 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognitive impairment is a poorly understood, serious, and emerging complication for adult patients with sickle cell disease. Because there is extensive microvascular damage from oxidative damage in sickle cell disease, the investigators hypothesize that this is also present in the cerebral microvasculature to cause cognitive impairment. The investigators plan to test this by correlating markers of inflammation and oxidative damage with cognitive performance and 7 Tesla brain MRI microvascular findings in these patients, with the long term goal of understanding the mechanisms and risk factors of cognitive impairment in sickle cell disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Neurovascular Determinants of Cognitive Function in Adults with Sickle Cell Disease is a study for adults 18 and older who have been diagnosed with Sickle Cell Disease (SCD). Many adult patients with SCD suffer from cognitive impairment (CI), a serious complication responsible for severe functional limitations, and whose pathogenesis, risk factors, and natural history are unknown. This research project will look at cognitive performance and 7 Tesla brain MRI findings along with markers of inflammation and oxidation to better understand the mechanism and risk factors. The investigators will complete a baseline assessment. SCD participants will be seen for follow-up at 3 and 5 years. Non-SCD participants will be seen for follow-up at 3 years. All assessments are completed at no cost and there is compensation for participation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SCD participant

No intervention

No interventions assigned to this group

Non-SCD participant

No intervention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 and above
2. Able to provide informed consent

For Non-SCD :

1. Between age 18 and 55
2. Able to provide informed consent
3. Are age, race, and gender matched to a Sickle Cell Disease study subject.

Exclusion Criteria

1. Age less than 18 years
2. Current pregnancy or lactation
3. Any medical condition that may result in neurocognitive or brain dysfunction that is not secondary to SCD including:

1. Diabetes mellitus
2. Coronary artery disease
3. Peripheral vascular disease
4. Other causes of cerebral vasculitis such as Systemic Lupus Erythematosus (SLE)
4. Any contraindication to MRI scanning including:

1. History of claustrophobia
2. Presence of metallic implants such as cardiac pacemaker or implantable defibrillator, surgical aneurysm clips, or any implanted device (e.g. insulin pump, drug infusion device)
3. Any known metal fragments embedded in the body (eg: ear implant)
4. Neural stimulator (e.g. Transcutaneous Electrical Nerve Stimulation Unit)
5. Metal in the eye (e.g. from machining)
6. Any metallic foreign body, shrapnel, or bullet
7. Inability to lie still for 30 minutes or more
5. Inability to provide direct consent
6. In a current medical or pain crisis as diagnosed by attending physician -
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Enrico M Novelli

Assistant Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Enrico Novelli, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12040139

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Codeine in Sickle Cell Disease
NCT00174538 COMPLETED PHASE1/PHASE2